Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
Bristol-Myers Squibb
National Cancer Institute (NCI)
National Cancer Institute (NCI)
BeOne Medicines
Synthekine
BeOne Medicines
National Institutes of Health Clinical Center (CC)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Gilead Sciences
BioNTech SE
Genmab
Merck Sharp & Dohme LLC
PrECOG, LLC.
Merck Sharp & Dohme LLC
Shanghai JMT-Bio Inc.
AstraZeneca
Xencor, Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Eli Lilly and Company
Pfizer
Mirati Therapeutics Inc.
Eli Lilly and Company
Hoffmann-La Roche
Hoffmann-La Roche
AstraZeneca
Merck Sharp & Dohme LLC
Incyte Corporation
Arcus Biosciences, Inc.
Revolution Medicines, Inc.
Verastem, Inc.
Wake Forest University Health Sciences
Hoffmann-La Roche
RemeGen Co., Ltd.
InxMed (Shanghai) Co., Ltd.
AstraZeneca
AstraZeneca
Shanghai Chest Hospital
AbbVie
UNICANCER
Janssen Research & Development, LLC
Pfizer
Bristol-Myers Squibb
AstraZeneca
Regeneron Pharmaceuticals
AbbVie
Thomas Jefferson University
Hoffmann-La Roche